Mindaugas Galvosas, MD
@mgalvosas.bsky.social did:plc:obfvh5sbhlapv2nooimkthu3
Neuroscience Digital Biomarkers @ indivi.io | prev. cough as a digital biomarker @ hyfe.com; founder of wandering prevention tech for dementia | interested in Digital Health | my opinions
Bluesky’a katılma tarihi:
- Takipçi
- 4.072
- Takip edilen
- 2.253
- Post
- 991
- Sıralamaya girdiği gün
- 0
Özet
Mindaugas Galvosas, MD (@mgalvosas.bsky.social), 7 Şubat 2024 tarihinde katılan bir Bluesky kullanıcısı. 4.072 takipçisi var, 2.253 hesabı takip ediyor ve 991 post paylaştı.
Sıralama geçmişi
Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.
Bu hesap henüz günlük sıralamaya girmedi.
Son beğendiği postlar
Bluesky ağındaki herkese açık beğeniler.
Giving up on deep space tonight with such a bright, but beautiful moon! #astrophotography
Postu gösterIf you haven’t read it yet👇 Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson’s Disease www.medrxiv.org/content/10.6...
Postu gösterIt was a really successful International Parkinson and Movement Disorder Society congress in Seoul this year for Indivi #MDSCongress #MDS2026
Postu gösterDo all DM1 therapies need to be oligonucleotides? What about: -> small molecules? -> engineered RNA-binding proteins? -> gene and repeat targeting? -> drug repurposing? Future DM1 therapies discussed at #WMS2026 will extend beyond oligonucleotides alone
Postu gösterIn his #WMS2026 talk "Advances in Translational Therapeutics for DM1," Prof. Masayuki Nakamori (Yamaguchi University) highlighted how quickly the DM1 pipeline has matured, and also what remains to be solved: the endpoint
Postu göster
Blokladığı hesaplar
Bluesky’da bloklar herkese açık kayıtlardır.
